Welcome to our dedicated page for Nurix Therapeutics news (Ticker: NRIX), a resource for investors and traders seeking the latest updates and insights on Nurix Therapeutics stock.
Nurix Therapeutics, Inc. (Nasdaq: NRIX) is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapies that modulate cellular protein levels. Leveraging their proprietary drug discovery platform, DELigase, Nurix focuses on a novel approach to target E3 ubiquitin ligases within the ubiquitin-proteasome system (UPS). This system regulates protein stabilization and degradation, providing therapeutic opportunities across various disease areas.
Founded by experts in the UPS field and initially funded by leading investors such as Third Rock Ventures and The Column Group, Nurix has positioned itself as a leader in developing first-in-class therapies. The company’s pipeline includes drug candidates that target protein degraders of Bruton's tyrosine kinase (BTK) and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B). Their lead product candidate, NX-2127, is an orally available BTK degrader designed to treat relapsed or refractory B-cell malignancies. Another key candidate, NX-1607, is an orally available CBL-B inhibitor aimed at immuno-oncology indications.
Partnering with industry giants like Celgene, Sanofi, Gilead, and Pfizer, Nurix continues to expand its reach and capabilities. One significant collaboration with Sanofi targets the STAT6 pathway, a critical player in type 2 inflammation. The extension of this collaboration underscores the success and productivity of their ongoing research efforts. Nurix’s innovative approach is also evident in their BTK degrader NX-5948, demonstrating promising clinical activity in patients with CNS involvement.
In its recent financial update, Nurix reported strong results for the first quarter of 2024, with increased revenue driven by collaborations and research milestones. Despite reporting a net loss, the company holds substantial cash reserves to support ongoing and future projects. Leadership transitions within Nurix, such as the appointment of Julia P. Gregory as the new board chair, reflect the company’s commitment to strategic growth and innovation.
Headquartered in San Francisco, California, Nurix remains at the forefront of drug discovery and development, aiming to bring transformative therapies to patients with cancer, inflammatory conditions, and other challenging diseases. For more information, visit http://www.nurixtx.com.
Nurix Therapeutics (NRIX) has received PRIME designation from the European Medicines Agency for NX-5948, its selective BTK degrader, for treating relapsed or refractory chronic lymphocytic leukemia patients who have previously received BTK and BCL-2 inhibitor therapy. The PRIME designation, which provides enhanced support for promising medicines addressing unmet medical needs, was granted based on encouraging safety and efficacy data from ongoing Phase 1 trials. NX-5948 has shown potential activity against mutations resistant to current BTK inhibitors, with pivotal trials planned for 2025.
Nurix Therapeutics (NRIX) presented preclinical data for two autoimmune and inflammatory disease programs at ACR Convergence 2024. The first program, NX-5948, is an oral BTK degrader showing potential superiority over kinase inhibitors in inflammatory diseases. The second program, GS-6791, developed with Gilead Sciences, is an IRAK4 degrader for rheumatoid arthritis treatment.
Both compounds demonstrated strong efficacy in preclinical models. NX-5948 showed superior results in arthritis models and other inflammatory conditions, while GS-6791 exhibited robust dose-dependent efficacy in arthritis models with better cytokine response reduction compared to IRAK4 kinase inhibitors.
Nurix Therapeutics announced upcoming presentations of data from its BTK degrader programs, NX-5948 and NX-2127, at the 66th ASH Annual Meeting in December 2024. The presentations include two oral sessions and one poster presentation. The first oral presentation will discuss efficacy and safety results from an ongoing Phase 1a/b study of NX-5948 in relapsed/refractory CLL patients. The second oral presentation will focus on how NX-2127 and NX-5948 affect T cell functionality in CLL. Additionally, a poster presentation will showcase studies on BTK degradation as a therapeutic strategy for relapsed CNS lymphoma.
Nurix Therapeutics (NRIX), a clinical stage biopharmaceutical company focused on targeted protein modulation drugs for cancer and inflammatory diseases, has announced its participation in five major investor conferences in November 2024. The company's leadership team, including CEO Arthur T. Sands, CFO Hans van Houte, and CBO Jason Kantor, will attend:
- Truist BioPharma Symposium (NY, Nov 7)
- UBS Healthcare Conference (CA, Nov 12)
- Stephens Biotechnology Virtual Fireside Chats (Nov 14)
- Stifel Healthcare Conference (NY, Nov 18)
- Jefferies London Healthcare Conference (UK, Nov 21)
Webcasts for the UBS, Stifel, and Jefferies conferences will be available on Nurix's website for 30 days post-event.
Nurix Therapeutics (Nasdaq: NRIX) announced presentations at the 7th Annual TPD & Induced Proximity Summit, October 28-31, 2024, in Boston. The company will present new preclinical data on a brain-penetrant, pan-mutant B-Raf degrader and recent clinical data from the NX-5948 BTK degrader program.
Key presentations include:
- An orally bioavailable, brain-penetrant pan-mutant B-RAF degrader showing potent anti-tumor activity in multiple disease models
- Clinical activity of NX-5948 in CLL & NHL, demonstrating utility in relapsed/refractory B-cell malignancies, including cases with CNS involvement and BTK inhibitor resistance mutations
Nurix executives will also participate in panel discussions on strategic partnerships and the future of targeted protein degradation. The company aims to showcase its leadership in the field and the therapeutic potential of its targeted protein modulation approach.
Nurix Therapeutics presented positive results from its ongoing Phase 1a/1b clinical trial of NX-5948, an oral BTK degrader, in patients with relapsed/refractory Waldenstrom's macroglobulinemia (WM) at the 12th International Workshop on Waldenstrom's Macroglobulinemia. Key findings include:
- 77.8% objective response rate (7 of 9 evaluable patients)
- Durable responses deepening over time
- Two patients on treatment for over a year
- Tolerable safety profile consistent with overall population
- Responses observed regardless of MYD88 and CXCR4 mutation status
The trial included heavily pretreated patients with a median of 3 prior lines of therapy. These results support the advancement of NX-5948 into the ongoing Phase 1b expansion cohort, including patients previously treated with BTK inhibitors and those with Bing-Neel syndrome.
Nurix Therapeutics (Nasdaq: NRIX) has appointed Anil Kapur to its board of directors, effective October 15, 2024. Mr. Kapur brings over 25 years of executive experience in pharmaceutical and biotech companies across U.S. and international markets. His expertise in commercial operations and launching novel drugs in hematology and oncology is particularly relevant to Nurix's pipeline.
Mr. Kapur's notable achievements include launching blockbuster drugs Imbruvica and Darzalex while at Johnson & Johnson. He has held senior leadership positions at various companies, including Geron , Actinium Pharmaceuticals, and Bristol-Myers Squibb. Nurix is preparing to advance NX-5948 into pivotal clinical testing in 2025 and is planning for future commercialization.
Nurix Therapeutics (NRIX) reported Q3 fiscal 2024 financial results and provided a corporate update. Key highlights include:
1. Initiated Phase 1b dose expansion of NX-5948 in chronic lymphocytic leukemia and other B-cell malignancies
2. Reinitiated enrollment for NX-2127 in a Phase 1a/b oncology trial
3. Presented preclinical data on Degrader-Antibody Conjugates (DACs)
4. Cash and marketable securities of $457.5 million
Financial results: Collaboration revenue was $12.6 million, down from $18.5 million in Q3 2023. R&D expenses increased to $55.5 million from $47.9 million. Net loss was $49.0 million or ($0.67) per share.
The company anticipates clinical data readouts in Q4 2024 and initiation of pivotal studies for NX-5948 in 2025.
Nurix Therapeutics (Nasdaq: NRIX) announced upcoming presentations of preclinical data at ACR Convergence 2024, the annual meeting of the American College of Rheumatology, held November 14-19, 2024, in Washington, D.C. The presentations will focus on two of Nurix's drug candidates:
1. NX-5948: A BTK degrader in Phase 1b development for B-cell malignancies and IND-enabling studies for autoimmune diseases. The poster will showcase its efficacy in suppressing BCR, TLR, and FcR signaling in immune cells and its performance in preclinical models of arthritis and other inflammatory diseases.
2. GS-6791/NX-0479: An IRAK4 degrader developed in collaboration with Gilead Sciences, currently in IND-enabling studies. The presentation will demonstrate its ability to inhibit TLR and IL-1R-driven inflammatory signaling and its effects in a preclinical arthritis model.
Nurix Therapeutics (Nasdaq: NRIX) announced three oral presentations at the 22nd Annual Discovery on Target conference in Boston, MA, from September 30 to October 3, 2024. The presentations highlight Nurix's DELigase platform capabilities in addressing difficult-to-drug target classes like E3 ligases and transcription factors. The company will present on:
1. A small molecule inhibitor of CBL-B for enhanced T-cell function
2. The chemical space of bi-functional degraders targeting the CNS, including their clinical stage BTK degrader NX-5948
3. Screening DNA binding proteins with DNA Encoded Libraries, focusing on transcription factors
The presentation slides will be available on Nurix's website from October 1, 2024.
FAQ
What is the current stock price of Nurix Therapeutics (NRIX)?
What is the market cap of Nurix Therapeutics (NRIX)?
What does Nurix Therapeutics, Inc. specialize in?
What is the significance of Nurix's DELigase platform?
Who are Nurix's major partners?
What are some of Nurix's key drug candidates?
How has Nurix performed financially in recent quarters?
Where is Nurix Therapeutics headquartered?
What recent leadership changes have occurred at Nurix?
What is the focus of Nurix's collaboration with Sanofi?
What are Nurix's plans for NX-5948?
How can I learn more about Nurix Therapeutics?
